UK markets close in 2 hours 37 minutes

Zur Rose Group AG (0RRB.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
388.00-11.00 (-2.76%)
As of 1:04PM GMT. Market open.
Full screen
Previous close399.00
Open398.00
Bid0.00 x 0
Ask0.00 x 0
Day's range384.00 - 399.50
52-week range384.00 - 399.50
Volume375
Avg. volumeN/A
Market cap3.369B
Beta (5Y monthly)0.49
PE ratio (TTM)N/A
EPS (TTM)-10.11
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    DocMorris goes European: new branding for marketplaces in Spain and France

    Heerlen/Barcelona, 11.02.2021 – DocMorris is taking the next step in implementing its new brand architecture on the way to becoming the European umbrella brand of the digital healthcare ecosystem of the Zur Rose Group. The successful launch of the new branding for the DocMorris pharmacy and the DocMorris+ healthcare platform in Germany marked just the beginning of a shift of paradigm to digital healthcare. This successful first step in Germany is now followed by PromoFarma, the leading brand for online pharmacy marketplaces in Spain, and DoctiPharma, the second biggest brand in France, who see their brand now linked to the DocMorris brand identity.The new brand appearance of PromoFarma and DoctiPharma underlines its brand evolutions by using the green heart as a symbol for health. The varying shades of green for the heart represent the variety of current and future health solutions, which can be made even more personal and individual thanks to digitalisation. The light green “by DocMorris” descriptor confirms its link and shows both marketplaces are part of the European healthcare ecosystem.DocMorris, best known in Germany, has been chosen by the Zur Rose Group as umbrella brand for its European healthcare ecosystem. The international success of the Christmas film “#Herzensangelegenheit” [a matter of the heart] emphasises the strength of the DocMorris brand and how the brand emotionally resonates with consumers across European markets. The cooperation with global healthcare company Novo Nordisk in Germany – with the intention to expand it across Europe – demonstrates how important it is to work with top-class partners in healthcare to bring the ecosystem to life under one single brand. Combining specialist knowledge from partners with consumer reach makes it possible to better enable people to manage their own health and improve their quality of life conveniently and flexibly. Gaining additional marketplace expertise in Spain and France within the healthcare ecosystem increases its attractiveness for consumers allowing for more product accessibility and faster time-to-market. With the ambition to expand further their product offering and providing additional digital services, PromoFarma and DoctiPharma will also benefit from the existing expertise under the DocMorris brand and many years of experience across the Zur Rose Group to make it even simpler for people to access healthcare.On this basis, the DocMorris healthcare ecosystem will enable people all over Europe to manage their health in one click – safely and easily. The healthcare ecosystem will make it possible for all users, medical specialists, pharmacists and healthcare service providers to experience the vision of seamless and personal 360-degree health journeys.The European DocMorris branding was developed with the famous international design agency Mucho of Barcelona, Spain.eHealth ecosystem contact Betül Susamis Unaran Chief Strategy and Digital Officer Email: betul.unaran@zurrose.com Phone +41 79 834 41 40

  • EQS Group

    The Zur Rose Group accelerates growth

    EQS Group-News: Zur Rose Group AG / Key word(s): Development of Sales21.01.2021 / 07:00 Press releaseThe Zur Rose Group accelerates growth - Revenue up 23.6 per cent in fourth quarter and 14.4 per cent in the full year 2020- Growth in all markets accelerates quarter on quarter - Number of active customers across the group rises to 10.5 million- DocMorris to become the umbrella brand for the European healthcare ecosystem - DocMorris+ healthcare platform and launch of the app represent strategic milestones - Digital healthcare platform of Zur Rose Group, Allianz Care, CSS and Visana sets new standards in Swiss healthcare- 2020 profit outlook confirmedThe Zur Rose Group exceeded its ambitious growth targets for 2020. Revenue rose sharply to CHF 1,751.9 million (including Medpex and Apotal[1]). This is equivalent to growth of 14.4 per cent in local currency terms. The fourth quarter of 2020 saw growth accelerate to 23.6 per cent year on year in local currency terms with revenue of CHF 506.7 million, well ahead of the previous quarter (July to September). By the end of 2020 the number of active customers[2] had risen by more than 50 per cent year on year to 10.5 million, a gain of 700,000 on the quarter.Considerable growth in all marketsThe Group saw a sharp year-on-year rise in revenue in the fourth quarter in all markets. In Germany, revenue (including Medpex and Apotal) was up 29.8 per cent in local currency terms. For the year as a whole, growth was 16.5 per cent in local currency terms. In the Swiss home market Zur Rose increased revenue by 10.0 per cent in the fourth quarter and 7.1 per cent in the full year, a growth rate well in excess of the market. The marketplace business in the Europe segment also grew strongly, with revenue rising 60.3 per cent in local currency terms in the fourth quarter. Over the year as a whole, growth was 73.5 per cent, with a peak seen during the lockdown in spring 2020.DocMorris is the umbrella brand for the Zur Rose healthcare ecosystem The Zur Rose Group is moving step by step from being a pure mail-order pharmacy to Europe's digital healthcare ecosystem. The first key building blocks of the ecosystem are the telemedicine provider TeleClinic acquired in 2020 and the cooperation with Novo Nordisk announced in January 2021 to improve the health journeys of people with obesity. The Zur Rose Group is emphasising this strategic orientation with a new brand architecture: DocMorris, the best known pharmacy brand in Germany, will be the umbrella brand for the intended European healthcare ecosystem. As a first step in implementing the new brand architecture, the DocMorris pharmacy and the DocMorris+ healthcare platform in Germany have adopted a new brand identity with a green heart as icon and a symbol for health. The varying shades of green for the heart reflect the variety of current and future services, which can be made even more convenient, personal and individual thanks to digitalisation: advice, drug therapy safety, chronic patient care, electronic prescriptions and medication plans. The new brand and its visual design with all its variants will be launched and adopted in stages in all core markets except Switzerland by 2026.DocMorris advertising film achieves over 147 million views around the worldThe new brand identity of DocMorris got off to an emotional start when the Zur Rose Group launched the DocMorris Christmas story "#TakeCare" https://www.youtube.com/watch?v=2N2eSsIWtNI. The ad went live in Germany, Spain, France and Switzerland in early December 2020, and achieved more than 147 million views worldwide, including 28 million views on YouTube, 109 million on Facebook and 10 million on other channels, making it one of the most watched online Christmas videos in the world.Launch of the DocMorris+ healthcare platformA new business model and a new era in health care provision in Germany started in December 2020 with the launch of DocMorris+. This platform provides easy and convenient access to all healthcare services in one place - from diagnosis with an online doctor to the drug or healthcare products needed. For the first time, customers can manage their health with a single app. The launch of the DocMorris+ app is a strategic milestone on the path towards an integrated healthcare platform. In the start phase the focus is on the capabilities of the partner network and OTC orders by mail order. As the platform grows, faster delivery options will be available to customers. Once a relevant volume of e-prescriptions has been generated, the tried-and-tested e-prescription module will also be activated.eHealth-Tec wins tender for the specialist e-prescription service as a partner to IBMIn November 2020 gematik, the software service provider of the German Federal Ministry of Health, awarded the contract for the specialist e-prescription service in Germany to IBM. Zur Rose subsidiary eHealth-Tec is involved in the implementation as a partner to IBM. This was based on the tender by gematik for the "provision of development services, computer centre infrastructure, system hardware and software as part of the launch of e-prescriptions". eHealth-Tec contributed with its accumulated experience as a systems provider for e-prescription solutions to the IBM bid. The implementation includes supplying the necessary infrastructure and operating and supporting the hardware and software components to be able to process the entire volume of e-prescriptions generated in Germany. The successful participation in the tender reinforces the role played by the Zur Rose Group as a pioneer in systematically introducing electronic prescriptions in Germany.Online consultations at TeleClinic rise by 500 per centZur Rose subsidiary TeleClinic expanded its position as Germany's leading telemedicine provider considerably in 2020. The number of consultations carried out over the telemedicine platform grew five-fold year on year. The increased patient demand was primarily due to the coronavirus pandemic and cost-free access for non-private patients for the first time. Thanks to its high quality standards, TeleClinic also secured its position with doctors and patients as the first port of call for digital healthcare. The offering from the Munich-based company made a major contribution towards ensuring healthcare provision across the country in 2020."Apps on prescription" appear in digital practicesSince October 2020 doctors in Germany have been able to prescribe not only medicines but also "apps on prescription". TeleClinic identified the potential of certified digital healthcare applications (DiGa) at an early stage and has developed the DiGa portal as the partner to the digital healthcare system in Germany. This provides doctors with an overview of applications that have been officially approved by the Federal Institute for Drugs and Medical Devices and other information relevant to treatment, giving patients easier access to medical apps. This allows both sides to benefit from the new offering. TeleClinic includes newly approved apps as a matter of priority.Allianz Care, CSS, Visana and Zur Rose Group launch digital healthcare platformIn November 2020 insurers Allianz Care, CSS, Visana and the Zur Rose Group established a joint venture to operate a comprehensive digital healthcare platform in Switzerland. The independent company sets a new benchmark in Swiss healthcare: it is laying the foundations for digitally supported, integrated care nationwide. The platform helps customers organise their personal healthcare at all stages of treatment. Patients have access to individually tailored, quality-assured healthcare services with a single click. The platform is open to all players in the healthcare sector: insurers, doctors, hospitals, pharmacies and other providers. When officially launched in the Swiss market in the second quarter of 2021 the platform will offer easy interactive access to healthcare for all Swiss residents. The core contribution by the Zur Rose Group will be to contribute some of the technology for the platform. Parts of the Zur Rose platform will be licensed to the joint venture for this purpose. Completion and market entry are subject to approval by the relevant competition authorities.Zur Rose increases market presence in French-speaking SwitzerlandIn December 2020 joint venture partners Zur Rose and Medbase, the Migros healthcare provider, opened their first shop-in-shop pharmacy in the Migros supermarket in Crissier in the canton of Vaud. Zur Rose is also keen to use its presence to boost the activities of its online pharmacy business in French-speaking Switzerland. The expansion of the online market presence was accompanied by an extensive marketing campaign which saw unprompted brand familiarity in French-speaking Switzerland almost double to 26 per cent.OutlookThe Zur Rose Group confirms the profit forecast for 2020: the expectation is to break even at the adjusted EBITDA level before expenditure on additional growth initiatives, especially in electronic prescriptions and European opportunities. From this year onwards the Group expects considerable growth in prescription drugs and confirms the medium-term revenue outlook of more than CHF 3 billion. The medium-term EBITDA margin target, adjusted for growth initiatives, is around 8 per cent. The introduction of mandatory electronic prescriptions from 2022 and the implementation of the healthcare ecosystem are also creating relevant potential for revenue and profit.The Annual Report 2020 will be published on 18 March 2021.The Zur Rose Group is planning to hold a Capital Markets Day in the second quarter of 2021. The precise date and agenda will be announced at a later date. Revenue, in CHF million (unaudited) 1.1.-31.12.2020 1.1.-31.12.2019 Change Zur Rose Group including Medpex/Apotal 1,751.9 1,568.7 11.7% Zur Rose Group including Medpex/Apotal, in local currency 14.4% Zur Rose Group 1,476.9 1,355.5 8.9% Zur Rose Group, in local currency 11.4% Markets Germany including Medpex/Apotal 1,096.2 976.0 12.3% Germany including Medpex/Apotal, in local currency 16.5% Germany 821.2 762.8 7.7% Germany, in local currency 11.7% Switzerland 593.1 553.7 7.1% Rest of Europe 66.4 39.7 67.3% Europe, in local currency 73.5% Business models B2C including Medpex/Apotal 1,236.2 1,106.2 11.7% B2C 961.1 893.1 7.6% Professional Services 453.1 422.8 7.2% Marketplace 66.4 39.7 67.3% Revenue, in CHF million (unaudited) 1.10.-31.12.2020 1.10.-31.12.2019 Change Zur Rose Group including Medpex/Apotal 506.7 412.0 23.0% Zur Rose Group including Medpex/Apotal, in local currency 23.6% Zur Rose Group 410.4 355.2 15.5% Zur Rose Group, in local currency 15.9% Markets Germany including Medpex/Apotal 330.9 256.3 29.1% Germany including Medpex/Apotal, in local currency 29.8% Germany 234.6 199.5 17.6% Germany, in local currency 18.0% Switzerland 158.2 143.9 10.0% Rest of Europe 18.8 11.8 59.5% Europe, in local currency 60.3% Business models B2C including Medpex/Apotal 369.4 291.9 26.5% B2C 273.0 235.1 16.1% Professional Services 119.7 107.7 11.2% Marketplace 18.8 11.8 59.5% The elimination of revenue between markets and business models is not shown separately.Investors and analyst contactChristoph Herrmann, Head of Investor RelationsEmail: ir@zurrose.com, phone: +41 58 810 11 49Media contactLisa Lüthi, Head of Group CommunicationsEmail: media@zurrose.com, phone: +41 52 724 08 14Agenda18 March 2021 2020 Full-Year Results20 April 2021 First Quarter Trading Update29 April 2021 Annual General Meeting19 August 2021 Half-Year Results21 October 2021 Q3 Trading UpdateZur Rose GroupThe Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2020 it generated revenue of CHF 1,752 million (including Medpex and Apotal) and currently has 10.5 million active customers in core European markets.With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.[1] As the separation of the mail-order business has not yet been completed, Medpex and Apotal had only a minor impact on the consolidated revenue of the Zur Rose Group.[2] Customers supplied by the Zur Rose Group, either directly or through its partners.End of Media Release Language: English Company: Zur Rose Group AG Walzmühlestrasse 60 8500 Frauenfeld Switzerland Phone: +41 52 724 08 14 Internet: www.zurrosegroup.com ISIN: CH0042615283 Listed: SIX Swiss Exchange EQS News ID: 1162093 End of News EQS Group News Service

  • EQS Group

    Zur Rose vindicated after court finds CEO Walter Oberhänsli not guilty

    EQS Group-News: Zur Rose Group AG / Key word(s): Legal Matter13.01.2021 / 16:10 Press releaseZur Rose vindicated after court finds CEO Walter Oberhänsli not guiltyThe Frauenfeld district court today found Walter Oberhänsli not guilty on all charges in connection with the prosecution for mail-order distribution of non-prescription drugs and rewarding doctors for issuing electronic prescriptions. The prosecution was based on a report of a criminal offence lodged by PharmaSuisse, the Swiss Pharmacists Association."I am delighted at the verdict from the Frauenfeld district court", said Walter Oberhänsli. "But actually there is much more at stake here: as a company we feel vindicated by this ruling in our ambition to make healthcare cheaper, more accessible and safer with digitalisation. The urgent need for further digitalisation in the Swiss healthcare system was made very apparent during the coronavirus crisis. The effective ban on mail-order distribution of non-prescription drugs is increasingly becoming a historical relict that has to be seen as anachronistic in the current environment and positively harmful to health when the coronavirus is rampant. What is urgently required now is the mandatory introduction of electronic prescriptions; numerous studies have shown that these increase patient safety and avoid the follow-up costs incurred as a result of media breaks and the absence of digital processes. For all these reasons we will continue to work for high-quality, safe and low-cost supply of pharmaceuticals."Investors and analyst contactChristoph Herrmann, Head of Investor RelationsEmail: ir@zurrose.com, phone: +41 58 810 11 49Media contactLisa Lüthi, Head of Group CommunicationsEmail: media@zurrose.com, phone: +41 52 724 08 14Agenda21 January 2021 Sales 202018 March 2021 2020 Full-Year Results20 April 2021 First Quarter Trading Update29 April 2021 Annual General Meeting19 August 2021 Half-Year Results21 October 2021 Q3 Trading UpdateZur Rose GroupThe Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and currently has around ten million active customers in core European markets.With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.End of Media Release Language: English Company: Zur Rose Group AG Walzmühlestrasse 60 8500 Frauenfeld Switzerland Phone: +41 52 724 08 14 Internet: www.zurrosegroup.com ISIN: CH0042615283 Listed: SIX Swiss Exchange EQS News ID: 1160452 End of News EQS Group News Service